Explainable Machine Learning for Predicting Early Gastric Cancer
Launched by WENZHOU CENTRAL HOSPITAL · Jun 27, 2025
Trial Information
Current as of July 24, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • all patients with a gastric tissue pathology result are included
- Exclusion Criteria:
- • unclear or incomplete pathology results
- • significant missing laboratory data
- • progressive and advanced gastric cancer
About Wenzhou Central Hospital
Wenzhou Central Hospital is a leading medical institution in China, dedicated to advancing healthcare through innovative clinical research and trials. With a commitment to excellence in patient care and a focus on multidisciplinary collaboration, the hospital plays a pivotal role in the development of new therapies and treatment protocols. Equipped with state-of-the-art facilities and a team of experienced healthcare professionals, Wenzhou Central Hospital strives to contribute to the global medical community by conducting rigorous clinical studies that adhere to the highest ethical standards and regulatory requirements. Through its research initiatives, the hospital aims to enhance patient outcomes and foster advancements in medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Wenzhou, Zhejiang, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported